More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$670.92B
EPS
6.58
P/E ratio
30.3
Price to sales
6.43
Dividend yield
1.923%
Beta
0.219933
Previous close
$282.55
Today's open
$278.99
Day's range
$277.56 - $281.72
52 week range
$195.90 - $290.25
show more
CEO
Joaquin Duato
Employees
140800
Headquarters
New Brunswick, NJ
Exchange
New York Stock Exchange
Shares outstanding
2.41B
Issue type
Common Stock
Healthcare
Pharmaceuticals
Here's How Much Passive Income $50,000 Generates in These 4 Dividend Aristocrats
Four household-name stocks have raised their dividends for 40 to 70 straight years, yet each one carries a risk that could threaten the streak. Which payout looks safest, and which check is biggest?
24/7 Wall Street • 7 hours ago

Invest $25,000 in These 4 Dividend Stocks to Start Building Retirement Income
Retirement changes what a portfolio is for. Once the paycheck stops, the number that matters most is how much cash the account sends back each year without pushing a sale of shares.
24/7 Wall Street • 4 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
GlobeNewsWire • a day ago

J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition
JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.
Zacks Investment Research • Nov 17, 2026

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts
J&J's $2.2 billion Ollin Biosciences deal adds a promising retinal disease candidate, building on acquisitions.
Zacks Investment Research • Nov 17, 2026

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research • Nov 17, 2026

Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Zacks Investment Research • Nov 17, 2026

Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson
DALLAS--(BUSINESS WIRE)--An appeals court in Louisiana has upheld a multimillion verdict against Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mesothelioma and death.In a Nov. 16 ruling, Louisiana's Fourth Circuit Court of Appeal affirmed a trial court's decision to increase damages awarded to the family of Jeannine Henderson. National plaintiffs trial firm Dean Omar Branham Shirley, LLP (DOBS) represented the Henderson family as well as.
Business Wire • Nov 17, 2026

3 Bulletproof Passive Income Dividend Kings to Buy and Hold Forever
A pending IRS ruling, rising commodity costs, and more test whether the payouts of these passive income Dividend Kings can survive.
24/7 Wall Street • Nov 17, 2026

Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield near 2.94%.
24/7 Wall Street • Nov 17, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Johnson & Johnson commission-free¹. Build wealth for the long term using automated trading and transfers.